Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $30.67 USD
Change Today -0.07 / -0.23%
Volume 137.0K
CYNO On Other Exchanges
Symbol
Exchange
CYNO is not on other exchanges.
As of 5:20 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

cynosure inc-a (CYNO) Snapshot

Open
$30.51
Previous Close
$30.74
Day High
$30.86
Day Low
$30.15
52 Week High
02/6/15 - $31.83
52 Week Low
07/28/14 - $18.63
Market Cap
666.5M
Average Volume 10 Days
235.9K
EPS TTM
$1.55
Shares Outstanding
21.7M
EX-Date
--
P/E TM
19.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for CYNOSURE INC-A (CYNO)

cynosure inc-a (CYNO) Related Businessweek News

View More BusinessWeek News

cynosure inc-a (CYNO) Details

Cynosure, Inc. develops and markets aesthetic treatment systems for plastic surgeons, dermatologists, and other medical practitioners. It offers Elite product line for hair removal, and treatment of facial and leg veins and pigmentations; SmartLipo product line for LaserBodySculpting for the removal of unwanted fat; Cellulaze product line for the treatment of cellulite; Affirm/SmartSkin product line for anti-aging applications, including treatments for wrinkles, skin texture, skin discoloration, and skin tightening; and Cynergy product line for the treatment of vascular lesions. The company also provides Accolade, MedLite C6, and RevLite product lines for the removal of benign pigmented lesions, as well as multi-colored tattoos; PicoSure product line for the treatment of tattoos, benign pigmented lesions, acne scars, fine lines, and wrinkles; Icon aesthetic system for hair removal, wrinkle reduction, and scar and stretch mark treatment; and Vectus diode laser for high volume hair removal. In addition, it distributes PinPointe FootLaser for the treatment of onychomycosis. The company’s aesthetic treatment systems utilizes a range of energy sources, including Pulse dye, Alexandrite, CO2, Diode, Erbium, Er:YAG, and Nd:YAG lasers; and intense pulsed light devices. It sells its products through a direct sales force in North America, France, Morocco, Germany, Spain, the United Kingdom, Australia, China, Japan, and Korea, as well as through independent distributors in approximately 120 countries. The company was founded in 1991 and is headquartered in Westford, Massachusetts.

755 Employees
Last Reported Date: 03/13/15
Founded in 1991

cynosure inc-a (CYNO) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $2.2M
President, Chief Operating Officer, Chief Fin...
Total Annual Compensation: $1.4M
Executive Vice President of Worldwide Sales
Total Annual Compensation: $1.0M
Compensation as of Fiscal Year 2013.

cynosure inc-a (CYNO) Key Developments

Cynosure, Inc. Presents at Sidoti & Company, LLC's 19th Annual Emerging Growth Research Institutional Investor Forum, Mar-17-2015

Cynosure, Inc. Presents at Sidoti & Company, LLC's 19th Annual Emerging Growth Research Institutional Investor Forum, Mar-17-2015 . Venue: The Grand Hyatt Hotel, 109 E 42nd St., New York, NY 10017, United States.

Cynosure Announces FDA Clearance of New 532 Nm Laser Delivery System for PicoSure

Cynosure, Inc. announced FDA 510(k) clearance of its new 532 nm Laser Delivery System for PicoSure, creating a powerful, dual-wavelength laser system for removing tattoos of all colors in fewer treatments. PicoSure, the world's first picosecond aesthetic laser, is widely recognized for its technology leadership, unmatched clinical versatility and proven performance. The new 532 nm Laser Delivery System further builds on the clinical and commercial success of the 755 nm PicoSure for the removal of tattoos and benign pigmented lesions as well as the treatment of acne scars and wrinkles. The integration of the 532 nm wavelength into the PicoSure platform allows for more effective removal of red, orange and yellow tattoo ink, which can now be cleared in fewer treatments.

Cynosure, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Cynosure, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. The company's total revenues for the fourth quarter of 2014 were $86.3 million, an increase of 16% compared with $74.5 million for the fourth quarter of 2013. Net income for the fourth quarter of 2014 was $23.0 million, or $1.05 per diluted share, compared with net income of $7.3 million, or $0.33 per diluted share, for the fourth quarter of 2013. Net income for the fourth quarter of 2014 included an income tax benefit of $19.6 million, or $0.89 per diluted share, resulting from the release of the income tax valuation allowance relating to net deferred tax assets. On a non-GAAP basis, excluding the income tax benefit relating to the release of the income tax valuation allowance, acquisition costs and amortization, fourth-quarter 2014 net income was $7.9 million, or $0.36 per diluted share, compared with non-GAAP net income of $9.2 million, or $0.41 per diluted share, in the same period of 2013. Income from operations was $8,266,000 against $8,250,000 a year ago. Income before income taxes was $6,926,000 against $8,142,000 a year ago. Non-GAAP income from operations was $11,630,000 against $13,245,000 a year ago. For the year, the company reported revenues of $292,369,000 against $226,010,000 a year ago. Income from operations was $21,260,000 against loss of $5,827,000 a year ago. Income before income taxes was $18,338,000 against loss of $5,537,000 a year ago. Net income was $31,338,000 or $1.41 per diluted share against loss of $1,647,000 or $0.09 per diluted share a year ago. Non-GAAP net income was $24,489,000 or $1.10 per diluted share against loss of $22,539,000 or $1.13 per diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYNO:US $30.67 USD -0.07

CYNO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Iridex Corp $10.68 USD +0.04
Lutronic Corp 34,950 KRW +100.00
PhotoMedex Inc $2.01 USD +0.10
Syneron Medical Ltd $12.38 USD +0.71
Zeltiq Aesthetics Inc $30.83 USD -0.61
View Industry Companies
 

Industry Analysis

CYNO

Industry Average

Valuation CYNO Industry Range
Price/Earnings 21.8x
Price/Sales 2.3x
Price/Book 1.9x
Price/Cash Flow 19.5x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYNOSURE INC-A, please visit www.cynosure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.